This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Emergent’s TRU-016 For CLL Receives Orphan Medicinal Product Designation From European Commission

Emergent BioSolutions Inc. (NYSE: EBS) today announced that the European Commission granted orphan medicinal product designation to Emergent’s humanized single chain monoclonal antibody against CD37, also called TRU-016, for the treatment of chronic lymphocytic leukemia (CLL).

“Receiving orphan medicinal product designation for TRU-016 from the European Commission, following orphan drug designation from the FDA in 2011, is an important step in the development of TRU-016 and underscores the medical need in treating B-cell malignancies like CLL,” said Scott C. Stromatt, M.D., senior vice president and chief medical officer of Emergent BioSolutions. “Emergent is pleased to receive these designations and we are looking forward to data from our ongoing CLL studies.”

Orphan designation of TRU-016 for CLL in Europe qualifies it for certain development and commercial incentives, including protocol assistance, access to centralized authorization procedures, reduced fees for regulatory activities, and ten years of market exclusivity after approval. In December 2011, Emergent announced that the United States Food and Drug Administration granted orphan drug designation to TRU-016 for the treatment of CLL.

TRU-016 is currently being evaluated in a randomized Phase 2 study (16201) in combination with bendamustine compared to bendamustine alone in relapsed CLL patients. The primary outcome measurement for this study is overall response rate and data are expected in the second half of 2013.

Data from the Phase 1b portion of the study (16201) were presented at the American Society of Hematology annual meeting on December 8, 2012. Results from this study indicated that TRU-016 in combination with bendamustine was well tolerated and showed a positive response.

In addition, the company initiated in November 2012 a Phase 1b, single-arm, open label study (16009) evaluating TRU-016 in combination with rituximab in previously untreated patients. The primary outcome measurement for this study is overall response rate and data are expected in the second half of 2013.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,068.79 +18.04 0.11%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,813.5790 +2.7910 0.06%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs